Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 138 clinical trials
featured
A Phase 1b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia

This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS

cancer
acute leukemia
leukemia
adult acute myelogenous leukemia
  • 101 views
  • 29 Dec, 2020
  • 8 locations
Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2

The purpose of this study is to assess the safety and tolerability of an 'AML Cell Vaccine' in patients with poor prognosis acute myeloid leukaemia (AML).

remission
graft versus host disease
  • 17 views
  • 07 Nov, 2020
  • 1 location
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3mut applying an accelerated titration design.

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

Quizartinib, a selective FLT3 inhibitor, is being developed as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The absolute oral bioavailability of quizartinib

  • 0 views
  • 13 May, 2021
  • 1 location
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74856665 as monotherapy (Arm A) and in combination with azacitidine (AZA) (Arm B).

human chorionic gonadotropin
cell transplantation
myeloid leukemia
refractory acute myeloid leukemia (aml)
azacitidine
  • 0 views
  • 23 Jun, 2021
  • 27 locations
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS. For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8. Two treatment arms will enroll …

cytarabine
venetoclax
induction chemotherapy
cell transplantation
refractory acute myeloid leukemia (aml)
  • 51 views
  • 14 May, 2021
  • 10 locations
Safety Tolerability PK PD and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Evaluate the safety and tolerability of AMG 427 in adult subjects with relapsed/refractory AML. Estimate the maximum tolerated dose (MTD) and / or a biologically optimal dose (eg, recommended phase 2 dose [RP2D]).

  • 10 views
  • 19 Jun, 2021
  • 38 locations
A Phase 1 First in Human Study of ZN-d5 as a Single Agent

with Non-Hodgkin Lymphoma (NHL) and subjects with Acute Myeloid Leukemia (AML).

blood transfusion
r-chop regimen
marginal zone lymphoma
mantle cell lymphoma
leukemia
  • 0 views
  • 19 Jun, 2021
  • 13 locations
Study of a New Intravenous Drug Called S65487 in Patients With Acute Myeloid Leukemia Non Hodgkin Lymphoma Multiple Myeloma or Chronic Lymphocytic Leukemia

))/ Recommended Phase 2 Doses (RP2D(s)) of S65487 as single agent administered intravenously (i.v.) in adult patients with refractory or relapsed Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma (NHL), Multiple

  • 17 views
  • 24 Feb, 2021
  • 17 locations
A Study of H3B-8800 in Participants With Myelodysplastic Syndromes Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

-8800 in subset of participants with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). The study consists of two parts, a dose escalation part

blood transfusion
myelomonocytic leukemia
induction chemotherapy
leukemia
hydroxyurea
  • 0 views
  • 23 Mar, 2021
  • 27 locations